Skip to main content
. 2022 Feb 24;14(5):1157. doi: 10.3390/cancers14051157

Figure 4.

Figure 4

Post hoc subgroup analyses of weighted Kaplan–Meier survival curve by clinically specific group after IPTW adjustment. (a) Pembrolizumab first line vs. second line and more; (b) Skin irAEs vs. Non–skin irAEs; (c) Pembrolizumab alone vs. combined chemotherapy; (d) Pembrolizumab fixed dose 100 mg vs. 200 mg.